Dianati Vahid, Shamloo Azar, Kwiatkowska Anna, Desjardins Roxane, Soldera Armand, Day Robert, Dory Yves L
Institut de Pharmacologie de Sherbrooke, IPS, Département de Chimie, Faculté des Sciences, Université de Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, Québec, J1H 5N4, Canada.
Département de Chimie, Centre Québécois sur les Matériaux Fonctionnels, Université de Sherbrooke, Sherbrooke, Québec, J1K 2R1, Canada.
ChemMedChem. 2017 Aug 8;12(15):1169-1172. doi: 10.1002/cmdc.201700300. Epub 2017 Jul 19.
PACE4, a member of the proprotein convertases (PCs) family of serine proteases, is a validated target for prostate cancer. Our group has developed a potent and selective PACE4 inhibitor: Ac-LLLLRVKR-NH . In seeking for modifications to increase the selectivity of this ligand toward PACE4, we replaced one of its P3 Val methyl groups with a basic group capable of forming a salt bridge with D160 of PACE4. The resulting inhibitor is eight times more potent than the P3 Val parent inhibitor and two times more selective over furin, because the equivalent salt bridge with furin E257 is not optimal. Moreover, the β-branched nature of the new P3 residue favors the extended β-sheet conformation usually associated with substrates of proteases. This work provides new insight for better understanding of β-sheet backbone-backbone interactions between serine proteases and their peptidic ligands.
PACE4是丝氨酸蛋白酶原蛋白转化酶(PCs)家族的成员之一,是前列腺癌的一个经过验证的靶点。我们团队开发了一种强效且具有选择性的PACE4抑制剂:Ac-LLLLRVKR-NH 。为了寻找能提高该配体对PACE4选择性的修饰方法,我们将其P3位缬氨酸的一个甲基替换为一个能够与PACE4的D160形成盐桥的碱性基团。所得抑制剂的效力比P3位缬氨酸的母体抑制剂高八倍,对弗林蛋白酶的选择性高两倍,因为与弗林蛋白酶E257形成的等效盐桥并不理想。此外,新P3残基的β-分支性质有利于通常与蛋白酶底物相关的延伸β-折叠构象。这项工作为更好地理解丝氨酸蛋白酶与其肽类配体之间的β-折叠主链-主链相互作用提供了新的见解。